Authors: Dinesh Kumar, Nilima, ter Ellen, Bram M., Bouma, Ellen M., Troost, Berit, van de Pol, Denise P. I., van der Ende-Metselaar, Heidi H., van Gosliga, Djoke, Apperloo, Leonie, Carpaij, Orestes A., van den Berge, Maarten, Nawijn, Martijn C., Stienstra, Ymkje, Rodenhuis-Zybert, Izabela A., Smit, Jolanda M.
Venue: N/A
Type: Publication
Abstract: AbstractAntiviral therapies are urgently needed to treat and limit the development of severe COVID-19 disease. Ivermectin, a broad-spectrum anti-parasitic agent, has been shown to have anti-SARS-CoV-2 activity in Vero cells at a concentration of 5 µM. These in vitro results triggered the investigation of ivermectin as a treatment option to alleviate COVID-19 disease. In April 2021, the World Health Organization stated, however, the following: “the current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive”. It is ...
(read more)
Topics: 
Virology
Pharmacology
Immunology
DOI:
10.1128/aac.01543-21
(Found 2 versions)
Loading (it may take a couple of seconds)...
Loading (it may take a couple of seconds)...